Internal Medicine · Rochester, NY
NPI
1720099856
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2561 Lac de Ville Blvd, Ste 100
Rochester, NY, 14618
Phone (585) 424-3410
Groups this clinician bills Medicare through
Medicare paid, 2024
$58K
913 services
Medicare patients, 2024
109
Average age 75
Drug cost, 2024
$2.1M
14,737 prescriptions
Company payments, 2025
$2,420
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charlene Vitale was code 99214 (office e&m - established), 433 times for 107 patients. In total Charlene Vitale billed 913 services in 27 codes, and Medicare paid $58K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-01-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 433 | 107 | $90.68 | $39K |
| 96372 Injection Administration | Office | 108 | 41 | $10.46 | $1,129 |
| 99213 Office E&M - Established | Office | 97 | 47 | $62.99 | $6,110 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 67 | 27 | $0.99 | $66.49 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 57 | 57 | $122.89 | $7,005 |
| 93000 Electrocardiogram | Office | 46 | 44 | $10.04 | $462 |
| 99442 Telephone Services | Office | 13 | 12 | $57.77 | $751 |
| 90656 Vaccine Product | Office | 13 | 13 | $21.90 | $285 |
| G0008 Administration of influenza virus vaccine | Office | 12 | 12 | $30.83 | $370 |
By year: 2022 $64K for 960 services; 2023 $52K for 795 services; 2024 $58K for 913 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82274 Immunoassay | 39 | 39 | $15.71 | $613 |
Medicare prescription drug claims, 2024
In 2024, the drug Charlene Vitale prescribed most often to Medicare patients was Rosuvastatin Calcium, with 834 prescriptions and refills. In total Charlene Vitale wrote 14,737 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 834 | 2,071 | 234 | $14K |
| Levothyroxine Sodium Generic | 665 | 1,843 | 172 | $9,092 |
| Dexamethasone Generic | 658 | 660 | 312 | $1,852 |
| Omeprazole Generic | 422 | 878 | 117 | $6,024 |
| Gabapentin Generic | 288 | 598 | 92 | $3,057 |
| Atorvastatin Calcium Generic | 283 | 776 | 78 | $3,764 |
| Ozempic Semaglutide | 272 | 321 | 51 | $260K |
| Repatha Sureclick Evolocumab | 265 | 319 | 48 | $171K |
| Duloxetine Hcl Generic | 249 | 462 | 63 | $5,544 |
| Metformin Hcl Generic | 248 | 497 | 82 | $1,037 |
| Jardiance Empagliflozin | 235 | 352 | 52 | $190K |
| Metoprolol Succinate Generic | 231 | 611 | 62 | $3,721 |
| Synthroid Levothyroxine Sodium | 220 | 589 | 52 | $25K |
| Eliquis Apixaban | 212 | 289 | 46 | $163K |
| Meloxicam Generic | 191 | 342 | 58 | $775 |
Brand drugs: 2,689 claims; generic drugs: 11,897 claims; opioid claims: 309.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charlene Vitale $2,420 ($2,420 in general payments such as food, travel and fees) from 13 companies. The largest payer was Amgen Inc. with $603.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 35 | $603 |
| AstraZeneca Pharmaceuticals LP AZN | 15 | $525 |
| Abbvie Inc. ABBV | 27 | $291 |
| Novo Nordisk Inc NVO | 19 | $287 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $250 |
| Pfizer Inc. PFE | 27 | $224 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $71.51 |
| Phathom Pharmaceuticals, Inc. PHAT | 7 | $50.36 |
| Paratek Pharmaceuticals, Inc. | 2 | $33.83 |
| GlaxoSmithKline, LLC. GSK | 1 | $30.97 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.